Researchers at the Max Planck Institute for Molecular Genetics have developed a novel synthetic micropeptide termed the ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous ...

Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to ...

Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention ...

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, ...

Amerigo Scientific offers PerKitsTM drug conjugation kits to simplify and optimize the conjugation of small-molecule drugs to biomolecules. NE ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...